APA (7th ed.) Citation

L, O., SK, K., CK, L., R, F., DK, B., S, A., . . . O, O. (2025). Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: Final results from an open-label, phase 2b, randomised controlled trial. The Lancet. Global health, 13(10), e1723. https://doi.org/10.1016/S2214-109X(25)00272-4

Chicago Style (17th ed.) Citation

L, Osei-Tutu, et al. "Sustained Efficacy of the RTS,S/AS01E Malaria Vaccine over 50 Months of Follow-up When Used in Full-dose or Fractional-dose Regimens in Young Children in Ghana and Kenya: Final Results from an Open-label, Phase 2b, Randomised Controlled Trial." The Lancet. Global Health 13, no. 10 (2025): e1723. https://doi.org/10.1016/S2214-109X(25)00272-4.

MLA (9th ed.) Citation

L, Osei-Tutu, et al. "Sustained Efficacy of the RTS,S/AS01E Malaria Vaccine over 50 Months of Follow-up When Used in Full-dose or Fractional-dose Regimens in Young Children in Ghana and Kenya: Final Results from an Open-label, Phase 2b, Randomised Controlled Trial." The Lancet. Global Health, vol. 13, no. 10, 2025, p. e1723, https://doi.org/10.1016/S2214-109X(25)00272-4.